For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Genzyme Corporation

USPTO Granted Patents = 824

% Expired Patents = 16.1

CIPO Patents = 26

EPO Patents = 257

Trademarks = 63

Forward Citations = 15,471

Loading Chart...

Loading Chart...

961 inventors (with patents filed for the assignee):

Seng H Cheng (54 out of 71 patents)

Craig S Siegel (41 out of 42 patents)

Huawei Qiu (33 out of 47 patents)

4. David J Harris (32 out of 32 patents)

5. Clark Qun Pan (32 out of 56 patents)

6. Alexander Hee-Hanson (31 out of 31 patents)

7. Robert J Miller (30 out of 30 patents)

8. Stephen Randall Holmes-Farley (29 out of 76 patents)

9. Robert Wilson (27 out of 27 patents)

10. Pradeep K Dhal (25 out of 40 patents)

11. Edward R Lee (25 out of 30 patents)

12. Thomas Lever (25 out of 25 patents)

13. James E Stefano (23 out of 29 patents)

14. Bradford Hirth (23 out of 34 patents)

15. Luis Z Avila (21 out of 38 patents)

Core Competencies:

Medicament Delivery Device

Gene Therapy

Macular Degeneration

Pompe Disease

Fluid Transfer Device

RNAi

Biomanufacturing

Antibody Detection

Ciliopathies

TRK Inhibitors

Flow Cytometry

Protein A Chromatography

824 patents: Sort by Forward Citations

1. 12753171 - 5-membered heteroarylaminosulfonamides for treating conditions mediated by deficient CFTR activity (2026-10-06),

2. 12735459 - MODIFIED ADENO-ASSOCIATED VIRAL CAPSID PROTEINS FOR OCULAR GENE THERAPY AND METHODS OF USE THEREOF (2026-09-15),

3. 12734307 - Medicament delivery device (2026-09-15),

4. 12734160 - Methods for treating symptoms and disorders associated with lysosomal storage diseases (2026-09-15),

5. 12691229 - Medicament delivery device (2026-07-28),

6. 12685307 - Ultra-high density cell banking methods (2026-07-21),

7. 12674003 - SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES (2026-07-07),

8. 12661305 - Vial adapter and injection kit for withdrawing a liquid medicament from an injection vial (2026-06-23),

9. 12661303 - Medical device for rolling and mixing a medicament within a medicament vial along a track (2026-06-23),

10. 12655200 - Methods of Treating Antibody-Mediated Disorders with FcRn Antagonists (2026-06-16),

11. 12649750 - Macrocyclic compounds, compositions, and methods of using thereof (2026-06-09),

12. 12642913 - Medicament delivery device (2026-06-02),

13. 12637653 - In-line product monitoring in integrated continuous bio-manufacturing (2026-05-26),

14. 12637414 - Arylamides and methods of use thereof (2026-05-26),

15. 12630810 - Polypeptide Having Beta-Hexosaminidase Activity, and Polynucleotides Coding for the Same (2026-05-19),

Company Overview

Genzyme Corporation, based in Cambridge, MA, specializes in the development and manufacturing of advanced medicament delivery devices. The company focuses on innovative solutions in gene therapy and treatments for conditions such as macular degeneration and Pompe disease. Genzyme is also engaged in biomanufacturing and the development of fluid transfer devices, employing cutting-edge technologies like RNA interference and antibody detection to enhance therapeutic efficacy and patient outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

824 Patents

#6 in Cambridge, MA

#36 in Massachusetts

#621 in US

#1,225 in the World

Cambridge, MA, United States of America

Genzyme Corporation

Forward Citations = 15,471

961 inventors:

Seng H Cheng (54 out of 71 patents)

Craig S Siegel (41 out of 42 patents)

Huawei Qiu (33 out of 47 patents)

4. David J Harris (32 out of 32 patents)

5. Clark Qun Pan (32 out of 56 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Genzyme Corporation. Retrieved from https://idiyas.com/company/genzyme

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…